Skip to main content

Advertisement

Advertisement

Advertisement

Advertisement

ADVERTISEMENT

Tumor Agnostic Education Center Disease State Hub

Tumor Agnostic
Education Center

News
11/05/2024
A single-center real-world study found the use of ipilimumab in the second-line was an effective therapy for patients with metastatic BRAF/NRAS-wildtype metastatic melanoma without brain metastases.
A single-center real-world study found the use of ipilimumab in the second-line was an effective therapy for patients with metastatic BRAF/NRAS-wildtype metastatic melanoma without brain metastases.
A single-center real-world study...
11/05/2024
Oncology
News
10/31/2024
A safety lead-in for the STARBOARD trial found that both doses of encorafenib under evaluation, in combination with binimetinib and pembrolizumab, demonstrated safety that was comparable to the known profile for each agent.
A safety lead-in for the STARBOARD trial found that both doses of encorafenib under evaluation, in combination with binimetinib and pembrolizumab, demonstrated safety that was comparable to the known profile for each agent.
A safety lead-in for the...
10/31/2024
Oncology
News
10/08/2024
According to phase 2 results, encorafenib plus binimetinib showed clinical activity for BRAF V600E-mutant advanced non-small cell lung cancer in the first-line setting.
According to phase 2 results, encorafenib plus binimetinib showed clinical activity for BRAF V600E-mutant advanced non-small cell lung cancer in the first-line setting.
According to phase 2 results,...
10/08/2024
Oncology
Conference Coverage
10/01/2024
According to updated data from the phase 2 PHAROS trial, encorafenib plus binimetinib showed prolonged efficacy, particularly among treatment-naïve patients, for BRAF V600E-mutant metastatic non-small cell lung cancer.
According to updated data from the phase 2 PHAROS trial, encorafenib plus binimetinib showed prolonged efficacy, particularly among treatment-naïve patients, for BRAF V600E-mutant metastatic non-small cell lung cancer.
According to updated data from...
10/01/2024
Oncology
News
08/09/2024
Though the phase 2 MATCH trial was terminated early due to poor accrual, vemurafenib did appear to be tolerable and a potential treatment option among pediatric patients with tumors harboring BRAF-V600 mutations.
Though the phase 2 MATCH trial was terminated early due to poor accrual, vemurafenib did appear to be tolerable and a potential treatment option among pediatric patients with tumors harboring BRAF-V600 mutations.
Though the phase 2 MATCH trial...
08/09/2024
Oncology
News
07/11/2024
According to final analysis results from the phase 3 COMBI-AD trial, adjuvant dabrafenib plus trametinib improved long-term recurrence-free and distant metastasis-free survival compared to placebo among patients with stage 3 melanoma...
According to final analysis results from the phase 3 COMBI-AD trial, adjuvant dabrafenib plus trametinib improved long-term recurrence-free and distant metastasis-free survival compared to placebo among patients with stage 3 melanoma...
According to final analysis...
07/11/2024
Oncology
News
06/20/2024
According to a phase 2 study, there was no difference in PFS between a combined immunotherapy regimen and a targeted therapy induction followed by combined immunotherapy among patients with BRAF/V600E/K mutant melanoma.
According to a phase 2 study, there was no difference in PFS between a combined immunotherapy regimen and a targeted therapy induction followed by combined immunotherapy among patients with BRAF/V600E/K mutant melanoma.
According to a phase 2 study,...
06/20/2024
Oncology
Rebecca Heist, MD, MPH, Massachusetts General Hospital
Conference Coverage
05/02/2024

Featuring Rebecca Heist, MD, MPH

Featuring Rebecca Heist, MD, MPH ...
At the Great Debates and Updates in Lung Cancer Meeting in New York, New York, Rebecca Heist, MD, MPH, debated in favor of using targeted therapy for patients with lung cancer who exhibit BRAF mutations or MET exon 14 skipping alterations.
At the Great Debates and Updates in Lung Cancer Meeting in New York, New York, Rebecca Heist, MD, MPH, debated in favor of using targeted therapy for patients with lung cancer who exhibit BRAF mutations or MET exon 14 skipping alterations.
At the Great Debates and Updates...
05/02/2024
Oncology
News
04/25/2024

Stephanie Holland 

Stephanie Holland 
Based on results from the FIREFLY-1 trial, the FDA has granted accelerated approval to tovorafenib for patients aged 6 months and older with relapsed or refractory pediatric low-grade glioma harboring a BRAF fusion, rearrangement, or a BRAF...
Based on results from the FIREFLY-1 trial, the FDA has granted accelerated approval to tovorafenib for patients aged 6 months and older with relapsed or refractory pediatric low-grade glioma harboring a BRAF fusion, rearrangement, or a BRAF...
Based on results from the...
04/25/2024
Oncology

Advertisement

Advertisement

Advertisement

Advertisement